Bug G, Labopin M, Byrne JL, Mielke S, et al. Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first Bone Marrow Transplant 2026 Mar 6. doi: 10.1038/s41409-026-02805.
PMID: 41792300